K
Klaus-Werner Schulte
Researcher at University of Düsseldorf
Publications - 59
Citations - 927
Klaus-Werner Schulte is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Melanoma & Basal cell carcinoma. The author has an hindex of 12, co-authored 59 publications receiving 814 citations.
Papers
More filters
Journal ArticleDOI
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter,Rudolf Stadler,Cornelia Mauch,Werner Hohenberger,Norbert H. Brockmeyer,Carola Berking,Cord Sunderkötter,Martin Kaatz,Klaus-Werner Schulte,Percy Lehmann,Thomas Vogt,Jens Ulrich,Rudolf A. Herbst,Wolfgang Gehring,Jan-Christoph Simon,Ulrike Keim,Peter Martus,Claus Garbe +17 more
TL;DR: Results showed no difference in survival in patients treated with complete lymph node dissection compared with observation only, and complete lymph nodes dissection should not be recommended in patients with melanoma with lymph node micrometastases of at least a diameter of 1 mm or smaller.
Journal ArticleDOI
Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of δ-aminolaevulinic acid
Clemens Fritsch,Percy Lehmann,Wilhelm Stahl,Klaus-Werner Schulte,E Blohm,K. Lang,Helmut Sies,Thomas Ruzicka +7 more
TL;DR: The results suggest that optimum irradiation time for superficial epithelial skin tumours may be as soon as 2 h after application of δ-aminolaevulinic acid, whereas for treatment of psoriatic lesions an application time of 6 h is more suitable.
Journal ArticleDOI
Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis
Axel Hauschild,Michael Weichenthal,Bernd-Rüdiger Balda,Jürgen C. Becker,Helmut H. Wolff,Wolfgang Tilgen,Klaus-Werner Schulte,Johannes Ring,Dirk Schadendorf,S. Lischner,Günter Burg,Reinhard Dummer +11 more
TL;DR: Adjuvant treatment of intermediate- and high-risk melanoma patients with low-dose IFNalpha2b and IL-2 is safe and well tolerated by most patients, but it does not improve disease-free or overall survival.
Journal Article
Differential Accumulation of Iodine-123-Iodobenzamide in Melanotic and Amelanotic Melanoma Metastases In Vivo
Rolf Larisch,Klaus-Werner Schulte,Henning Vosberg,Thomas Ruzicka,Hans-Wilhelm Müller-Gärtner +4 more
TL;DR: The data suggest that the tracer does not bind to membrane dopamine receptors of the tumor but is built in or closely bound to intracellular melanin, which points to another mechanism of IBZM binding to melanoma cells.
Journal ArticleDOI
Ex vivo Application of δ-Aminolevulinic Acid Induces High and Specific Porphyrin Levels in Human Skin Tumors: Possible Basis for Selective Photodynamic Therapy
Clemens Fritsch,Janine Batz,Klaus Bolsen,Klaus-Werner Schulte,Matthias Zumdick,Thomas Ruzicka,Giinter Goerz +6 more
TL;DR: The tumor‐specific δ‐aminolevulinic acid metabolism indicates additional porphyrin metabolites such as coproporphyrIn apart from protoporphyr in as effective photosensitizers and may offer a novel approach to tumor‐selective photodynamic damage.